In a January New York Times article, “Should Patients Be Told of Better Care Elsewhere,” the author, Denise Grady, discusses a friend who was diagnosed with rectal cancer and needed surgery, radiation and chemotherapy. The friend consulted [...]
On March 6 and 7, the LRG Research Team met for the second in-person meeting at Brigham & Women’s Hospital in Boston, Mass. The Team had previously met in Portland, Oregon at Oregon Health & [...]
The following article was reprinted from an email alert sent by LegisLink Action Center, a community education service of US Oncology. On September 16, the Centers for Medicare & Medicaid Services (CMS) broadened the scope [...]
Pat George, LRG member and volunteer is well-known in the community. Pat recently took it upon himself to help educate the local students
KIT functions in several distinct cell types. Keep reading to learn about KIT signaling and new approaches for GIST Therapy.
This article explains hereditary GIST. Familial cancer syndrome is a genetic condition that causes an increased risk for specific types of cancers. Familial cancer syndromes account for only five to ten percent of all [...]
Gleevec was approved by the Food and Drug Administration (FDA) to prevent Gastrointestinal Cancer(imatinib mesylate) for a new indication. This will keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor [...]
On November 20, 2008, the LRG held its Fifth Annual Poker Tournament at the Midtown Loft on Fifth Avenue in New York City. It is always a remarkable evening and has become a muchlooked- forward-to event for LRG staff and supporters.
Interpreting research: dilemmas facing patients and physicians. Recently, GIST discussion groups have debated the value of the LRG study that examined dosage levels and survival rates. It is important for us to have this debate in [...]
In the span of a few weeks, representatives from the LRG traveled all over the country to attend events and gatherings relevant to the GIST community.
